We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+3.16%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.43B
AUM Growth
+$53M
Cap. Flow
+$216M
Cap. Flow %
8.89%
Top 10 Hldgs %
47.1%
Holding
78
New
18
Increased
12
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$82.2M
2
ALKS icon
Alkermes
ALKS
+$81.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$62.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$61.1M
5
GERN icon
Geron
GERN
+$55.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$85.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$68.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$56.9M
4
IMVT icon
Immunovant
IMVT
+$39.5M
5
ALBO
Albireo Pharma Inc
ALBO
+$36.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
PUT
argenx
ARGX
$55.3B
$37.3M 1.53%
+100,000
New +$37M
VRDN icon
27
Viridian Therapeutics
VRDN
$2.18B
$31.3M 1.29%
1,230,259
-540,895
-31% -$17.3M
AUTL
28
Autolus Therapeutics
AUTL
$386M
$27.6M 1.13%
15,000,000
– –
ETNB
29
DELISTED
89bio
ETNB
$27.4M 1.13%
1,800,000
-2,050,000
-53% -$26.7M
DYN icon
30
Dyne Therapeutics
DYN
$4.23B
$26.9M 1.1%
2,334,633
-349,567
-13% -$4.54M
RPTX
31
DELISTED
Repare Therapeutics
RPTX
$26.8M 1.1%
2,727,606
– –
NRIX icon
32
Nurix Therapeutics
NRIX
$2.5B
$26.6M 1.09%
2,997,830
+731,261
+32% +$7.62M
NTLA icon
33
Intellia Therapeutics
NTLA
$1.56B
$26.3M 1.08%
704,533
+4,533
+0.6% +$178K
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$24.2M 0.99%
1,816,531
– –
DCPH
35
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$21.1M 0.87%
+1,363,201
New +$22.8M
EWTX icon
36
Edgewise Therapeutics
EWTX
$4.36B
$20.5M 0.84%
3,068,259
-306,135
-9% -$2.84M
VIGL
37
DELISTED
Vigil Neuroscience
VIGL
$19.8M 0.81%
2,025,137
-79,037
-4% -$888K
INZY
38
DELISTED
Inozyme Pharma
INZY
$18.6M 0.76%
3,250,000
– –
QURE icon
39
uniQure
QURE
$2.79B
$17.4M 0.72%
+865,767
New +$18.2M
PNT
40
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$17M 0.7%
+2,345,073
New +$17.4M
ABOS icon
41
Acumen Pharmaceuticals
ABOS
$157M
$16M 0.66%
3,952,000
– –
ALLK
42
DELISTED
Allakos
ALLK
$16M 0.66%
3,585,000
-1,314,179
-27% -$8.41M
ACRS icon
43
Aclaris Therapeutics
ACRS
$728M
$13.8M 0.57%
+1,708,971
New +$21.7M
NUVB icon
44
Nuvation Bio
NUVB
$2.33B
$12.8M 0.53%
7,720,688
-500,500
-6% -$1.01M
SLN
45
Silence Therapeutics
SLN
$548M
$12.1M 0.5%
1,951,580
– –
RAPT
46
DELISTED
RAPT Therapeutics
RAPT
$10.5M 0.43%
71,404
-91,714
-56% -$18.5M
JNCE
47
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7.88M 0.32%
4,259,653
– –
RLMD icon
48
Relmada Therapeutics
RLMD
$556M
$6.41M 0.26%
2,837,818
– –
ORTX
49
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$6.27M 0.26%
+1,166,670
New +$6.34M
HRTX icon
50
Heron Therapeutics
HRTX
$95.5M
$4.88M 0.2%
3,234,722
-3,262,254
-50% -$8.17M
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Deep Track Capital held 78 positions worth $2.43B, up 2.2% from $2.38B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deep Track Capital deployed $216M of net new capital in Q1 2023, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $39.5M trimmed.

  • Deep Track Capital's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2023, an estimated $61.1M increase.
  • Deep Track Capital's biggest Q1 2023 reduction was Immunovant, cutting an estimated $39.5M.
  • Deep Track Capital fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $85.5M.
  • Deep Track Capital's ten largest holdings make up 47% of its $2.43B portfolio in Q1 2023.
  • Deep Track Capital opened 18 new positions and closed 20 in Q1 2023.
  • Deep Track Capital's portfolio value rose 2.2% quarter-over-quarter to $2.43B.

Based on Deep Track Capital's 13F filing for Q1 2023, filed 15 May 2023.